MBX CEO Buys 18,500 Shares as Stock Jumps 270% This Past Year. Here's What You Should Know

Key Points
The president & CEO of MBX Biosciences reported the acquisition of 18,500 indirectly held shares for about $526,000 on March 13, 2026.
The indirect holdings (486,777 shares) are maintained via the P. Kent Hawryluk Revocable Trust, as disclosed in the filing footnotes.
The transaction continues a net accumulation trend, consistent with prior administrative filings and capacity available for further purchases.
- 10 stocks we like better than Mbx Biosciences ›
P. Kent Hawryluk, the president & CEO of MBX Biosciences (NASDAQ:MBX), reported an open-market purchase of 18,500 indirectly held shares at a weighted average price of $28.41 per share on March 13, 2026, according to an SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Shares traded | 18,500 |
| Transaction value | $526,000 |
| Post-transaction common shares (direct) | 728,274 |
| Post-transaction common shares (indirect) | 486,777 |
| Post-transaction value (direct ownership) | ~$20.39 million |
Transaction value based on SEC Form 4 weighted average purchase price ($28.41); post-transaction value based on March 13, 2026 market close ($28.00).
Key questions
- How does the purchase size compare to Hawryluk's historical activity?
The executive has two other open-market purcahses of MBX stock on record, including one in October and another in February. - What is the structure of Hawryluk's ownership post-transaction?
After the transaction, Hawryluk holds 728,274 common shares directly and 486,777 common shares indirectly through the P. Kent Hawryluk Revocable Trust. - How material is this purchase relative to total holdings and market context?
The purchase represented 1.55% of Hawryluk's aggregate holdings, as reported in the Form 4, and occurred at a time when MBX Biosciences shares had appreciated 270% over the prior year.
Company overview
| Metric | Value |
|---|---|
| Market capitalization | $1.4 billion |
| Net income (TTM) | -$86.97 million |
| 1-year price change | 270% |
Company snapshot
- MBX develops clinical-stage precision peptide therapies targeting endocrine and metabolic disorders, with lead candidates in hypoparathyroidism, post-bariatric hypoglycemia, and obesity.
- The firm operates a research-driven model focused on advancing proprietary drug candidates through early- and mid-stage clinical trials, aiming for future regulatory approval and commercialization.
- It targets healthcare providers, endocrinologists, and patients affected by rare endocrine and metabolic conditions.
MBX Biosciences is a clinical-stage biotechnology company specializing in the development of innovative peptide-based therapies for endocrine and metabolic diseases. The company's pipeline includes differentiated assets addressing unmet medical needs, supported by a focused research and development strategy. With a lean operational structure and a strong emphasis on precision medicine, MBX Biosciences seeks to establish a competitive position in the rare disease therapeutics market.
What this transaction means for investors
This purchase looks like an indication of continued conviction rather than opportunistic timing, especially given the modest sizing relative to total holdings and the fact that the shares were acquired indirectly through a trust. The filing notes the stake sits within the P. Kent Hawryluk Revocable Trust, with Hawryluk disclaiming beneficial ownership beyond pecuniary interest, which limits how much weight investors should place on it as a pure insider bet.
At MBX Biosciences, the fundamentals remain the bigger story. Shares have surged roughly 270% over the past year, but the company is still early in its clinical lifecycle. Its lead asset is advancing toward a Phase 3 trial in hypoparathyroidism, expected to begin in the third quarter, while additional catalysts are stacked across 2026, including Phase 2 data and obesity pipeline updates. Importantly, MBX reported about $459 million in cash and investments, which management expects will fund operations into 2029.
The takeaway is that insider buying, even through a trust, can reinforce alignment but does not change the core risk profile. The trajectory of clinical readouts and the transition into late-stage development will matter far more than transactions like this.
Should you buy stock in Mbx Biosciences right now?
Before you buy stock in Mbx Biosciences, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Mbx Biosciences wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $497,659!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,095,404!*
Now, it’s worth noting Stock Advisor’s total average return is 912% — a market-crushing outperformance compared to 185% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of March 26, 2026.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.